Management
Basil M. Hantash, MD, PhD, MBA (Founder, Chairman, & CEO)
Dr. Hantash is an 18-year veteran of regenerative medicine, conducting pioneering research at Stanford University investigating the mechanisms underlying mesenchymal stem cell immune tolerance. In late 2006, Dr. Hantash founded Escape Therapeutics based on his lab's discovery while at Stanford University. He previously served as consulting CSO of Stemedica Cell Technologies, helping secure Series A financing while guiding technology, regulatory, intellectual property, and business development strategies.In 2002, Dr. Hantash founded ZyBas, Inc, a consulting firm focused on supporting early-stage disruptive aesthetic medicine companies such as Reliant Technologies, creators of the breakthrough Fraxel® medical laser platform. Prior to this, Dr. Hantash was a research scientist at the neuroscience biotech start-up Molecular Geriatrics, where he worked under the mentorship of Nobel Laureat Ferid Murad, MD, PhD.
Dr. Hantash completed his dermatology residency, postdoctoral training in the Program for Regenerative Medicine, and a prestigious fellowship in the Biodesign Innovation Program at Stanford University. He received his MD and PhD (pharmacology and physiology) from New Jersey Medical School, where he was inducted in the AOA Medical Honor Society and graduated as valedictorian of both his Graduate and Medical School. Dr. Hantash received his BS in Biology and minor in Chemistry from the University of Illinois, where he was the recipient of a Howard Hughes Research Fellowship. Dr. Hantash completed his MBA with honors at the Wharton School, University of Pennsylvania, where he was also the recipient of the Price Institute Fellowship for entrepreneurship.
